Want to see VDRM full AI Analyst Report?
ViaDerma (VDRM) AI Stock Analysis
Top Page
ViaDerma
(Other OTC:VDRM)
ViaDerma shows strong revenue growth and high gross profit margins, but faces significant challenges including declining profitability, high leverage, and a lack of detailed cash flow data. Technical indicators are insufficient for thorough analysis, and valuation metrics suggest the stock is overvalued. Earnings call data provides limited additional insights.
ViaDerma (VDRM) vs. SPDR S&P 500 ETF (SPY)
Not enough price history over this period.
- Market Cap
- $123.37K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 28.7
- Beta (1Y)
- -0.11
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 75
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
ViaDerma Business Overview & Revenue Model
Company Description
ViaDerma, Inc., a specialty pharmaceutical enterprise based in the United States, focuses on both the development and commercialization of pharmaceutical products. It also licenses its proprietary technology to other companies within the pharmaceutic...
How the Company Makes Money
ViaDerma generates revenue through the commercialization and sales of its proprietary topical products, particularly Vitastem. The company earns money by directly selling its products to healthcare providers, pharmacies, and distributors. Additionall...
ViaDerma Peers Comparison
Overall Rating
CPHI56Neutral
SNOA42Neutral- VDRM41Neutral
PRFX38Underperform
SHPH32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CPHI | 56Neutral | $26.88M | -0.62 | -17.14% | ― | -10.97% | 71.83% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SNOA | 42Neutral | $5.27M | -0.90 | -53.56% | ― | 47.00% | 50.49% |
| VDRM | 41Neutral | $123.37K | 28.74 | -0.48% | ― | ― | ― |
| PRFX | 38Underperform | $2.22M | -0.07 | -72.87% | ― | ― | ― |
| SHPH | 32Underperform | $24.54M | -0.17 | -156.78% | ― | ― | 94.90% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VDRM | ViaDerma, Inc. | ― | ― | ― | |
| CPHI | China Pharma | 0.62 | -1.01 | -61.72% | |
| SNOA | Sonoma Pharmaceuticals, Inc. | 1.10 | -2.68 | -70.90% | |
| PRFX | Painreform Ltd. | 0.73 | -5.07 | -87.41% | |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | 5.15 | -25.85 | -83.39% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 02, 2025